ATE277947T1 - Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung - Google Patents

Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung

Info

Publication number
ATE277947T1
ATE277947T1 AT98939708T AT98939708T ATE277947T1 AT E277947 T1 ATE277947 T1 AT E277947T1 AT 98939708 T AT98939708 T AT 98939708T AT 98939708 T AT98939708 T AT 98939708T AT E277947 T1 ATE277947 T1 AT E277947T1
Authority
AT
Austria
Prior art keywords
immunogenic
polypetids
altered cell
cell localization
recombinant vector
Prior art date
Application number
AT98939708T
Other languages
English (en)
Inventor
Marie-Paule Kieny
Jean-Marc Balloul
Nadine Bizouarne
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE277947T1 publication Critical patent/ATE277947T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT98939708T 1997-07-18 1998-07-17 Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung ATE277947T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9709152A FR2766091A1 (fr) 1997-07-18 1997-07-18 Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
PCT/FR1998/001576 WO1999003885A1 (fr) 1997-07-18 1998-07-17 Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee

Publications (1)

Publication Number Publication Date
ATE277947T1 true ATE277947T1 (de) 2004-10-15

Family

ID=9509372

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98939708T ATE277947T1 (de) 1997-07-18 1998-07-17 Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung

Country Status (11)

Country Link
US (2) US6884786B1 (de)
EP (1) EP0989999B1 (de)
JP (2) JP4489288B2 (de)
AT (1) ATE277947T1 (de)
AU (1) AU749054B2 (de)
CA (1) CA2296797C (de)
DE (1) DE69826661T2 (de)
ES (1) ES2229528T3 (de)
FR (1) FR2766091A1 (de)
PT (1) PT989999E (de)
WO (1) WO1999003885A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118754B1 (en) * 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
DE19925199A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
US7348014B2 (en) * 2000-04-14 2008-03-25 Transgene, S.A. Poxvirus with targeted infection specificity
AR032712A1 (es) * 2001-02-21 2003-11-19 Solvay Pharm Bv Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
EP1515987A2 (de) * 2002-04-24 2005-03-23 Universite Libre De Bruxelles Mutiertes hpv-16 e7 polypeptid, pharmazeutische zusammensetzung davon und verfahren zur seiner herstellung
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
US7732166B2 (en) * 2005-11-15 2010-06-08 Oncohealth Corporation Detection method for human pappilomavirus (HPV) and its application in cervical cancer
AR052743A1 (es) * 2006-04-11 2007-03-28 Inst Nac De Tecnologia Agropec Vector plasmidico de transferencia y virus canarypox recombinante
CN101426810A (zh) * 2006-04-21 2009-05-06 特朗斯吉恩股份有限公司 基于hpv-18的乳头瘤病毒疫苗
CN101426811A (zh) * 2006-04-21 2009-05-06 特朗斯吉恩股份有限公司 基于hpv-16的乳头瘤病毒疫苗
CN101063142B (zh) * 2006-04-30 2012-08-22 中国医学科学院基础医学研究所 人乳头瘤病毒16型dna疫苗和基因佐剂及其应用
ES2611975T3 (es) 2006-06-20 2017-05-11 Transgene S.A. Procedimiento para producir poxvirus y composiciones de poxvirus
WO2008140474A1 (en) * 2006-10-26 2008-11-20 Johns Hopkins University Recombinant adenovirus vaccines
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8859218B2 (en) 2008-06-13 2014-10-14 Oncohealth Corp. In situ detection of early stages and late stages HPV infection
PE20081723A1 (es) 2007-01-30 2008-12-14 Transgene Sa Vacuna contra el papilomavirus
BRPI0810305A2 (pt) * 2007-05-15 2018-07-10 Transgene Sa "vetor, molécula de ácido nucléico substancialmente isolada, célula hospedeira, composição farmacêutica, uso de uma molécula de ácido nucléico, uso de um vetor, uso de uma célula hospedeira e uso de uma composição"
EP2160402A2 (de) * 2007-05-15 2010-03-10 Transgene SA Signalpeptide
EA019836B1 (ru) * 2007-11-02 2014-06-30 Те Джонс Хопкинс Юниверсити Композиции многотипных пептидов hpv и способы лечения или предотвращения папилломавирусной инфекции у человека
US20090117123A1 (en) * 2007-11-02 2009-05-07 National Health Research Institutes Immunopeptides of hpv e6 and e7 proteins
MX2011007494A (es) 2009-01-13 2011-08-12 Transgene Sa Uso de una fraccion de la mitocondria de acidos nucleicos de saccharomyces cerevisiae para la estimulacion inmune.
MX2011007386A (es) 2009-01-20 2011-08-03 Transgene Sa Icam-1 soluble como un biomarcador para la prediccion de una respuesta terapeutica.
WO2010108908A1 (en) 2009-03-24 2010-09-30 Transgene Sa Biomarker for monitoring patients
JP5661738B2 (ja) 2009-04-17 2015-01-28 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． 患者をモニターするためのバイオマーカー
CN102449479B (zh) 2009-05-07 2015-11-25 安科健康公司 鉴别高度或≥cin2用于人乳头瘤病毒(hpv)与hpv相关癌症的早期及晚期检测、筛检和诊断
NZ596595A (en) 2009-05-12 2013-05-31 Transgene Sa Method for orthopoxvirus production and purification
CA2767458A1 (en) 2009-07-10 2011-01-13 Bruce Acres Biomarker for selecting patients and related methods
IN2012DN01577A (de) 2009-07-21 2015-06-05 Transgene Sa
BR112012002628B1 (pt) 2009-08-07 2021-09-08 Transgene Sa Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes
WO2011073741A1 (en) 2009-12-18 2011-06-23 Transgene Sa A method and a system for automatically processing multiple measurements of biological quantifiable parameters
JP5819851B2 (ja) 2010-01-08 2015-11-24 オンコヘルス コーポレーション Ｈｐｖ関連の癌の治療及びスクリーニングのための細胞に基づいた高処理能力ｈｐｖ免疫アッセイ
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
EP3628396B1 (de) 2012-04-06 2024-11-20 Life Technologies Corporation Flüssigkeitsmischsystem
WO2014009438A2 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
US10765731B2 (en) 2014-01-09 2020-09-08 Transgene Sa Fusion of heterooligomeric mycobacterial antigens
EP3552615B8 (de) 2014-07-16 2022-03-02 Transgene Onkolytisches virus zur expression von immunologischen prüfpunktmodulatoren
AU2015357225B2 (en) 2014-12-01 2020-04-09 Transgene Sa Stable liquid vaccinia virus formulations
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
JP7078535B2 (ja) 2015-12-29 2022-05-31 ライフ テクノロジーズ コーポレイション 横方向に変位された可撓性駆動線を有する流体混合システム及び使用方法
EP3452081A1 (de) 2016-05-04 2019-03-13 Transgene SA Kombinationstherapie mit cpg-tlr9-liganden
TW201825674A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
EP3522920A2 (de) 2016-10-10 2019-08-14 Transgene SA Immuntherapeutisches produkt und mdsc-modulator-kombinationstherapie
US11052147B2 (en) 2017-05-15 2021-07-06 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
CA3061678A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
JP7334124B2 (ja) 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
US11293003B2 (en) 2018-01-17 2022-04-05 Life Technologies Corporation Configurable fluid mixing system housing and support hardware
WO2019170820A1 (en) 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
EP3847246A1 (de) 2018-09-06 2021-07-14 Bavarian Nordic A/S Pockenviruszusammensetzungen mit verbesserter lagerung
CN113453712A (zh) 2018-12-28 2021-09-28 特兰斯吉恩股份有限公司 M2缺陷型痘病毒
AU2020350137A1 (en) 2019-09-20 2022-04-28 Merck Patent Gmbh Combination of a poxvirus encoding HPV polypeptides and IL-2 with an anti-PD-L1 antibody
WO2021180943A1 (en) 2020-03-12 2021-09-16 Bavarian Nordic A/S Compositions improving poxvirus stability
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
AU2023300419A1 (en) 2022-07-01 2025-01-02 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
WO2024121380A1 (en) 2022-12-08 2024-06-13 Pierre Fabre Medicament Vaccinal composition and adjuvant

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
FR2583429B1 (fr) 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
FR2583770B1 (fr) 1985-06-21 1988-08-19 Transgene Sa Expression de l'il-2 humaine dans les cellules de mammiferes par un poxvirus recombine
FR2606029B2 (fr) * 1986-04-08 1989-02-03 Transgene Sa Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus
FR2600079B1 (fr) * 1986-06-16 1989-10-20 Transgene Sa Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus
FR2643817B1 (fr) * 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
FR2617715B1 (fr) 1987-07-07 1990-08-31 Transgene Sa Vecteur viral et adn recombinant codant pour une ou des proteines de surface (ha et/ou f) d'un morbillivirus, culture cellulaire infectee, proteines obtenues, vaccin et anticorps obtenus
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
SE9101433D0 (sv) * 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DE69233639T2 (de) 1991-07-19 2007-05-31 Csl Ltd., Parkville Polynukleotidabschnitt des HPV16-Genoms
US5348867A (en) * 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
WO1994017187A1 (en) * 1993-01-29 1994-08-04 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services CLONING AND EXPRESSION OF PLASMODIUM FALCIPARUM TRANSMISSION-BLOCKING TARGET ANTIGEN, Pfs230
EP0689551B1 (de) * 1993-03-17 2008-02-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
WO1996039178A1 (en) 1995-06-05 1996-12-12 The Wistar Institute Of Anatomy And Biology A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
EP1019435A4 (de) * 1996-01-29 2001-12-12 Univ Georgetown Amplifizierung der wirksamkeit exprimierter rekombinanter proteine
FR2762615B1 (fr) 1997-04-28 1999-07-16 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes et vecteur le contenant
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
CA2302339A1 (en) * 1997-09-20 1999-04-01 Osiris Therapeutics, Inc. Antigen presenting mesenchymal stem cells

Also Published As

Publication number Publication date
AU749054B2 (en) 2002-06-20
US7332478B2 (en) 2008-02-19
ES2229528T3 (es) 2005-04-16
EP0989999A1 (de) 2000-04-05
PT989999E (pt) 2005-01-31
JP2010057500A (ja) 2010-03-18
DE69826661D1 (de) 2004-11-04
FR2766091A1 (fr) 1999-01-22
JP2001510201A (ja) 2001-07-31
CA2296797C (fr) 2011-02-08
AU8812798A (en) 1999-02-10
DE69826661T2 (de) 2005-10-06
EP0989999B1 (de) 2004-09-29
JP4489288B2 (ja) 2010-06-23
US6884786B1 (en) 2005-04-26
US20050159386A1 (en) 2005-07-21
WO1999003885A1 (fr) 1999-01-28
CA2296797A1 (fr) 1999-01-28

Similar Documents

Publication Publication Date Title
DE69826661D1 (de) Antitumorale zusammenstellung von immunogene polypetiden mit veränderter zellokalisierung
FI971783A7 (fi) Adenoviruksia, joissa ei ole elinkykyisiä kontaminoivia partikkeleita, niiden valmistus ja käyttöjä
EP0722461A4 (de) Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird
AR017510A1 (es) Polinucleotido aislado o recombinante, vector de expresion, celula huesped, metodo para preparar un polipeptido antigenico, metodo y equipo para ladeteccion de un polinucleotido, compuesto de union, metodo de empleo del compuesto de union, polipeptido antigenico aislado o substancialmente puro, ymet
AU1750297A (en) Humanized green fluorescent protein genes and methods
DE69417252D1 (de) Verbesserte immunogene zusammensetzung gegen mensliches gastrin 17
DK1222298T3 (da) Vektorer og fremgangsmåder til rekombinant proteinekspression
CA2094027A1 (en) Osteogenic peptides
DE69131882D1 (en) Asiloglycoproteine des hepatitis c-virus
AU8700291A (en) Hcv-specific peptides, agents therefor and the use thereof
ES2218872T3 (es) Polipeptido 10 de tipo citoquina de mamifero.
NZ518999A (en) Vaccine compositions
DE69841015D1 (de) Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2
EP1156103A3 (de) Oplophorus Luciferase
ATE331801T1 (de) Defektive rekombinante adenoviren mit einem inaktivierten gen iv a 2
WO2000012741A3 (fr) Systeme d'expression inductible
DE69738671D1 (de) Peptidantagonisten von dp transkriptionsfaktoren
ATE531730T1 (de) Immunogene hybridpolypeptide mit wirkung gegen obesitas und diese enthaltende impstoffzusammensetzung mit wirkung gegen obesitas
BR0008187A (pt) Controle biológico de nematódeos
DE69928947D1 (de) Moraxella catarrhalis basb034 polypeptide und verwendungen davon
WO2001098355A3 (en) Cgi-69 compositions and methods of use
NO962023L (no) Endotelin-konverterende enzym
GB2409680A (en) Methods for controlling proliferation of cells
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
TH42371A (th) พอลิเพพไทด์ปลายตัด e1 และ e2 ชนิดใหม่ของเฮพา?ไททิสซี ตลอดจนวิธีที่จะได้มัน

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0989999

Country of ref document: EP